Smith and Nephew's new chief executive officer (CEO) makes cost-effectiveness the key
This article was originally published in Clinica
Smith & Nephew chief executive, Chris O'Donnell, tells Martin Hedges he is happy to buck the merger trend and explains his philosophy for the company.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.